| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ENTA | Exit | Enanta Pharmaceuticals, Inc. | $0 | – | -22,750 | -100.0% | -3.54% | – |
| HIMS | Exit | Hims & Hers Health, Inc. | $0 | – | -306,431 | -100.0% | -5.13% | – |
| QSI | Exit | Quantum-Si Incorporated | $0 | – | -633,626 | -100.0% | -5.23% | – |
| ACET | Exit | Adicet Bio, Inc. | $0 | – | -170,000 | -100.0% | -7.26% | – |
| KNTE | Exit | Kinnate Biopharma Inc. | $0 | – | -291,667 | -100.0% | -10.46% | – |
| CMPX | Exit | Compass Therapeutics, Inc. | $0 | – | -1,554,250 | -100.0% | -10.64% | – |
| GMTX | Exit | Gemini Therapeutics, Inc. | $0 | – | -2,435,125 | -100.0% | -11.99% | – |
| Exit | Theseus Pharmaceuticals, Inc. | $0 | – | -959,275 | -100.0% | -16.70% | – | |
| Exit | Pardes Biosciences Inc | $0 | – | -5,227,307 | -100.0% | -29.04% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Pardes Biosciences Inc | 4 | Q3 2022 | 57.4% |
| Theseus Pharmaceuticals, Inc. | 4 | Q3 2022 | 16.7% |
| Gemini Therapeutics, Inc. | 4 | Q3 2022 | 12.0% |
| Quantum-Si Incorporated | 4 | Q3 2022 | 10.5% |
| Kinnate Biopharma Inc. | 4 | Q3 2022 | 10.5% |
| Compass Therapeutics, Inc. | 4 | Q3 2022 | 10.6% |
| Adicet Bio, Inc. | 4 | Q3 2022 | 7.3% |
| Enanta Pharmaceuticals, Inc. | 3 | Q3 2022 | 3.5% |
| Cue Health Inc. | 2 | Q1 2022 | 13.7% |
| Cullinan Oncology, Inc. | 2 | Q1 2022 | 4.8% |
View Foresite Capital Opportunity Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 4 | 2023-08-31 |
| 4 | 2023-07-19 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
| 4 | 2023-01-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 3 | 2022-06-13 |
View Foresite Capital Opportunity Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.